Serotonin receptors involved in vasopressin and oxytocin secretion

Journal of Neuroendocrinology

Volumn 15, Issue 3, 2003, Pages 242-249

  Jørgensen, Henrik ^a   Riis, M ^a   Knigge, U ^a,b   Kjaer A ^a,b   Warberg, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 HT1A receptor; 5 HT2A+2C; 5 HT3 receptor; 5 HT4 receptor; 5 HT7 receptor; Neuroendocrine regulation; Oxytocin; Serotonin; Vasopressin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 [2 (METHANESULFONAMIDO)ETHYL] 4 PIPERIDINYL] 1 PROPANONE; 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINO 1 (6 CHLORO 2 PYRIDYL)PIPERIDINE; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 3 PIPERIDINOPROPYL ESTER; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 CARBAMOYLTRYPTAMINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; AZASETRON; CYANOPINDOLOL; METERGOLINE; METHYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXYTOCIN; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; TROPISETRON; UNINDEXED DRUG; VASOPRESSIN;

ANIMAL EXPERIMENT; BLOOD SAMPLING; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HORMONAL REGULATION; HORMONE INHIBITION; MALE; NONHUMAN; OXYTOCIN RELEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; REVIEW; SEROTONINERGIC SYSTEM; STATISTICAL ANALYSIS; VASOPRESSIN RELEASE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTHALAMUS, ANTERIOR; INJECTIONS, INTRAVENTRICULAR; MALE; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; VASOPRESSINS;

EID: 0037373005     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2826.2003.00978.x     Document Type: Review

References (44)

1. Falke N. Modulation of oxytocin and vasopressin release at the level of the neurohypophysis. Prog Neurobiol 1991; 36: 465-484.
2. Reichlin S. Neuroendocrinology. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Textbook of Endocrinology. Philadelphia: WB Saunders, 1998: 165-248.
3. Sawchenko PE, Swanson LW, Steinbusch HW, Verhofstad AA. The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res 1983; 277: 355-360.
4. Ferris CF, Melloni JR, Koppel G, Perry KW, Fuller RW, Delville Y. Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters. J Neurosci 1997; 17: 4331-4340.
5. Larsen PJ, Hay SA, Vrang N, Mikkelsen JD. Origin of projections from the midbrain raphe nuclei to the hypothalamic paraventricular nucleus in the rat: a combined retrograde and anterograde tracing study. Neuroscience 1996; 70: 963-988.
6. Iovino M, Steardo L. Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur J Pharmacol 1985; 113: 99-103.
7. Steardo L, Iovino M. Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin-angiotensin system. Brain Res 1986; 382: 145-148.
8. Saydoff JA, Rittenhouse PA, Carnes M, Armstrong J, Van de Kar LD, Brownfield MS. Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin. Am J Physiol 1996; 270: E513-E521.
9. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res 1983; 280: 176-179.
10. Faull CM, Charlton JA, Butler TJ, Baylis PH. The effect of acute pharmacological manipulation of central serotonin neurotransmission on osmoregulated secretion of arginine vasopressin in the rat. J Endocrinol 1993; 139: 77-87.
11. Hashimoto K, Ohno N, Murakami K, Kageyama J, Aoki Y, Takahara J. The effect of serotonin agonist 1-(trifluoromethylphenyl)-piperazine on corticotropin releasing factor and arginine vasopressin in rat hypothalamic nuclei. Endocrinol Jpn 1982; 29: 383-388.
12. Levy AD, Li Q, Alvarez Sanz MC, Rittenhouse PA, Brownfield MS, Van de Kar LD. Repeated cocaine modifies the neuroendocrine responses to the 5- HT1C/5-HT2 receptor agonist DOI. Eur J Pharmacol 1992; 221: 121-127.
13. Li Q, Brownfield MS, Battaglia G, Cabrera TM, Levy AD, Rittenhouse PA, Van de Kar LD. Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HC1 (DOI). J Pharmacol Exp Ther 1993; 266: 836-844.
14. Uvnas-Moberg K, Hillegaart V, Alster P, Ahlenius S. Effects of 5-HT agonists, selective for different receptor subtypes, on oxytocin, CCK, gastrin and somatostatin plasma levels in the rat. Neuropharmacology 1996; 35: 1635-1640.
15. Anderson IK, Martin GR, Ramage AG. Central administration of 5-HT activates 5-HT1A receptors to cause sympathoexcitation and 5-HT2/5-HT1C receptors to release vasopressin in anaesthetized rats. Br J Pharmacol 1992; 107: 1020-1028.
16. Van de Kar LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol 1991; 31: 289-320.
17. Pergola PE, Sved AF, Voogt JL, Alper RH. Effect of serotonin on vasopressin release: a comparison to corticosterone, prolactin and renin. Neuroendocrinology 1993; 57: 550-558.
18. Jorgensen H, Knigge U, Kjaer A, Warberg J. Stress-induced neurohypophysial hormone secretion is partly mediated by serotonergic neurons. Abstracts of the International Union of Pharmacology IV. Rotterdam: IUPAR, 1998: 112.
19. Jorgensen H, Knigge U, Kjaer A, Warberg J. Adrenocorticotropic Hormone secretion in rats induced by stimulation with serotonergic compounds. J Neuroendocrinol 1999; 11: 283-290.
20. Jorgensen H, Knigge U, Warberg J. Effect of selective serotonin receptor agonists on prolactin secretion in male rats. Neuroendocrinology 1993; 57: 401-407.
21. Jorgensen H, Knigge U, Warberg J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5- hydroxytryptophan. Neuroendocrinology 1992; 55: 336-343.
22. Kjaer A, Knigge U, Rouleau A, Garbarg M, Warberg J. Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons. Endocrinology 1994; 135: 675-681.
23. Montes R, Johnson AK. Efferent mechanisms mediating renal sodium and water excretion induced by centrally administered serotonin. Am J Physiol 1990; 259: R1267-R1273.
24. Uvnas-Moberg K, Bjokstrand E, Hillegaart V, Ahlenius S. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacol Berl 1999; 142: 95-101.
25. Spinedi E, Gaillard RC. Stimulation of the hypothalamo-pituitary-adrenocortical axis by the central serotonergic pathway: involvement of endogenous corticotropin-releasing hormone but not vasopressin. J Endocrinol Invest 1991; 14: 551-557.
26. Hillhouse EW, Milton NGN. Effect of acetylcholine and 5-hydroxytryptamine on the secretion of corticotrophin-releasing factor-41 and arginine vasopressin from the rat hypothalamus in vitro. J Endocrinol 1989; 122: 713-718.
27. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 1993; 268: 18200-18204.
28. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203.
29. Bagdy G, Kalogeras KT. Stimulation of 5-HT1A and 5-HT2/5-HT1C receptors induce oxytocin release in the male rat. Brain Res 1993; 611: 330-332.
30. Li Q, Brownfield MS, Levy AD, Battaglia G, Cabrera TM, Van de Kar LD. Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biol Psychiatry 1994; 36: 300-308.
31. Van de Kar LD, Levy AD, Li Q, Brownfield MS. A comparison of the oxytocin and vasopressin responses to the 5-HT1A agonist and potential anxiolytic drug alnespirone (S-20499). Pharmacol Biochem Behav 1998; 60: 677-683.
32. Bagdy G, Calogero AE, Szemeredi K, Gomez MT, Murphy DL, Chrousos GP, Gold PW. Beta-endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action. Brain Res 1990; 537: 227-232.
33. Bagdy G, Sved AF, Murphy DL, Szemeredi K. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur J Pharmacol 1992; 210: 285-289.
34. Brownfield MS, Greathouse J, Lorens SA, Armstrong J, Urban JH, Van de Kar LD. Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology 1988; 47: 277-283.
35. Herndon JL, Ismaiel A, Ingher SP, Teitler M, Glennon RA. Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem 1992; 35: 4903-4910.
36. Dedeoglu A, Fisher LA. Central and peripheral injections of the 5-HT2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, modify cardiovascular function through different mechanisms. J Pharmacol Exp Ther 1991; 259: 1027-1034.
37. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res, 1988; 8: 59-81.
38. Schechter LE, Simansky KJ. 1-(2,5-Dimethoxy-4-iodophenyl)-2-amino-propane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats. Psychopharmacol Berl 1988; 94: 342-346.
39. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP. SB 242084, a selec-tive and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997; 36: 609-620.
40. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Laporte AM, Gozlan H, Hamon M, Dourish CT. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 1996; 73: 337-353.
41. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav 2001; 69: 643-652.
42. Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol 1998; 274: G827-G831.
43. Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746-748.
44. Eglen RM, Bley K, Bonhaus DW, Clark RD, Hegde SS, Johnson LG, Leung E, Wong EH. RS 23597-190: a potent and selective 5-HT4 receptor antagonist. Br J Pharmacol 1993; 110: 119-126.